Cargando…

Assessing barriers to access and equity for COVID-19 vaccination in the US

BACKGROUND: Historical vaccination coverage in economically disadvantaged, ethnic minority, non-affluent white and agricultural populations in the US has lagged coverage in more affluent urban and suburban white populations due to a variety of social and economic factors. In the current COVID-19 pan...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuehn, Michael, LaMori, Joyce, DeMartino, Jessica K., Mesa-Frias, Marco, Doran, Jason, Korrapati, Lohit, Bhojwani, Rhea, Lefebvre, Patrick, Kirson, Noam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719622/
https://www.ncbi.nlm.nih.gov/pubmed/36463172
http://dx.doi.org/10.1186/s12889-022-14636-1
_version_ 1784843363482075136
author Kuehn, Michael
LaMori, Joyce
DeMartino, Jessica K.
Mesa-Frias, Marco
Doran, Jason
Korrapati, Lohit
Bhojwani, Rhea
Lefebvre, Patrick
Kirson, Noam
author_facet Kuehn, Michael
LaMori, Joyce
DeMartino, Jessica K.
Mesa-Frias, Marco
Doran, Jason
Korrapati, Lohit
Bhojwani, Rhea
Lefebvre, Patrick
Kirson, Noam
author_sort Kuehn, Michael
collection PubMed
description BACKGROUND: Historical vaccination coverage in economically disadvantaged, ethnic minority, non-affluent white and agricultural populations in the US has lagged coverage in more affluent urban and suburban white populations due to a variety of social and economic factors. In the current COVID-19 pandemic, sociocultural and economic challenges continue to present significant obstacles to achieving equitable uptake of COVID-19 vaccines. The goal of this study was to qualitatively assess perceptions of key US healthcare stakeholders of the most significant barriers to COVID-19 vaccine access and equity to better characterize their expected impact on US communities. METHODS: After conducting a targeted literature review (TLR), we hypothesized 20 high-impact barriers which included structural and logistical barriers, capturing systemic challenges to vaccine accessibility, and attitudinal and informational barriers, affecting patient willingness to pursue vaccination. We developed a qualitative discussion guide, which included both open-ended and closed-ended questions, and interview stimulus material to conduct one-on-one in-depth interviews to assess the expected prevalence, severity, and persistence of these 20 high-impact barriers, which were hypothesized based on TLR. As a part of this qualitative study, we conducted one-on-one in-depth interviews with a diverse set of 15 US healthcare stakeholders who were involved in the COVID-19 vaccine rollout in states with relatively disparate vaccination rates by ethnicity. These stakeholders were selected to reflect an array of roles in the COVID-19 vaccine rollout, including infectious disease specialists, pharmacists, community advocacy representatives, and partners of local governments involved in the COVID-19 vaccine rollout and community education. RESULTS: Respondents identified limited vaccination sites in rural settings and technology-related barriers as the most prevalent and severe structural and logistical barriers in US communities. Respondents assessed COVID-19 vaccine safety concerns and politically motivated skepticism to be the most prevalent and severe attitudinal and informational barriers. Respondents cited proliferation of mobile vaccination clinics and local community messaging to endorse vaccines as the most effective solutions to these top structural and attitudinal barriers. Respondents expected politically motivated skepticism to be the most significant and persistent barrier to broader vaccine uptake in the US. CONCLUSIONS: Our study suggests that attitudinal barriers, particularly politically motivated skepticism, are likely to remain the most persistent challenges to widespread vaccination against COVID-19 in the US.
format Online
Article
Text
id pubmed-9719622
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-97196222022-12-05 Assessing barriers to access and equity for COVID-19 vaccination in the US Kuehn, Michael LaMori, Joyce DeMartino, Jessica K. Mesa-Frias, Marco Doran, Jason Korrapati, Lohit Bhojwani, Rhea Lefebvre, Patrick Kirson, Noam BMC Public Health Research BACKGROUND: Historical vaccination coverage in economically disadvantaged, ethnic minority, non-affluent white and agricultural populations in the US has lagged coverage in more affluent urban and suburban white populations due to a variety of social and economic factors. In the current COVID-19 pandemic, sociocultural and economic challenges continue to present significant obstacles to achieving equitable uptake of COVID-19 vaccines. The goal of this study was to qualitatively assess perceptions of key US healthcare stakeholders of the most significant barriers to COVID-19 vaccine access and equity to better characterize their expected impact on US communities. METHODS: After conducting a targeted literature review (TLR), we hypothesized 20 high-impact barriers which included structural and logistical barriers, capturing systemic challenges to vaccine accessibility, and attitudinal and informational barriers, affecting patient willingness to pursue vaccination. We developed a qualitative discussion guide, which included both open-ended and closed-ended questions, and interview stimulus material to conduct one-on-one in-depth interviews to assess the expected prevalence, severity, and persistence of these 20 high-impact barriers, which were hypothesized based on TLR. As a part of this qualitative study, we conducted one-on-one in-depth interviews with a diverse set of 15 US healthcare stakeholders who were involved in the COVID-19 vaccine rollout in states with relatively disparate vaccination rates by ethnicity. These stakeholders were selected to reflect an array of roles in the COVID-19 vaccine rollout, including infectious disease specialists, pharmacists, community advocacy representatives, and partners of local governments involved in the COVID-19 vaccine rollout and community education. RESULTS: Respondents identified limited vaccination sites in rural settings and technology-related barriers as the most prevalent and severe structural and logistical barriers in US communities. Respondents assessed COVID-19 vaccine safety concerns and politically motivated skepticism to be the most prevalent and severe attitudinal and informational barriers. Respondents cited proliferation of mobile vaccination clinics and local community messaging to endorse vaccines as the most effective solutions to these top structural and attitudinal barriers. Respondents expected politically motivated skepticism to be the most significant and persistent barrier to broader vaccine uptake in the US. CONCLUSIONS: Our study suggests that attitudinal barriers, particularly politically motivated skepticism, are likely to remain the most persistent challenges to widespread vaccination against COVID-19 in the US. BioMed Central 2022-12-03 /pmc/articles/PMC9719622/ /pubmed/36463172 http://dx.doi.org/10.1186/s12889-022-14636-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Kuehn, Michael
LaMori, Joyce
DeMartino, Jessica K.
Mesa-Frias, Marco
Doran, Jason
Korrapati, Lohit
Bhojwani, Rhea
Lefebvre, Patrick
Kirson, Noam
Assessing barriers to access and equity for COVID-19 vaccination in the US
title Assessing barriers to access and equity for COVID-19 vaccination in the US
title_full Assessing barriers to access and equity for COVID-19 vaccination in the US
title_fullStr Assessing barriers to access and equity for COVID-19 vaccination in the US
title_full_unstemmed Assessing barriers to access and equity for COVID-19 vaccination in the US
title_short Assessing barriers to access and equity for COVID-19 vaccination in the US
title_sort assessing barriers to access and equity for covid-19 vaccination in the us
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719622/
https://www.ncbi.nlm.nih.gov/pubmed/36463172
http://dx.doi.org/10.1186/s12889-022-14636-1
work_keys_str_mv AT kuehnmichael assessingbarrierstoaccessandequityforcovid19vaccinationintheus
AT lamorijoyce assessingbarrierstoaccessandequityforcovid19vaccinationintheus
AT demartinojessicak assessingbarrierstoaccessandequityforcovid19vaccinationintheus
AT mesafriasmarco assessingbarrierstoaccessandequityforcovid19vaccinationintheus
AT doranjason assessingbarrierstoaccessandequityforcovid19vaccinationintheus
AT korrapatilohit assessingbarrierstoaccessandequityforcovid19vaccinationintheus
AT bhojwanirhea assessingbarrierstoaccessandequityforcovid19vaccinationintheus
AT lefebvrepatrick assessingbarrierstoaccessandequityforcovid19vaccinationintheus
AT kirsonnoam assessingbarrierstoaccessandequityforcovid19vaccinationintheus